Bear,
From Dr. K-Z’s presentation (see link at right on Agoracom page), we know:
-
there were 288 patients with CKD, with 124 on apabetalone and 164 on placebo
- only 6% of CKD patients were on SGLT2 inhibitors (N=17)
- change in eGFR over time did not differ between the apabetalone and placebo CKD groups
-
there was no change in HbA1c in either the apabetalone or placebo CKD groups
Thus, most of the SGLT2i patients were not in the CKD group and the significant results were derived primarily from the non-CKD cohort. With only 17 CKD patients on SGLT2i, and the low proportion of CKD patients receiving apabetalone, the sample sizes for the CKD cohort were just too small to provide good data.
Jupe
